PD Dr. J. Rech

Publications: Priv.-Doz. Dr. med. J. Rech

Valor-Méndez L, Voskens C, Rech J, Kleyer A, Schett G: Herpes simplex infection in a patient with rheumatoid arthritis treated with baricitinib: a case report. Rheumatology (Oxford). 2021;60(4): e122-e123
Vodencarevic A, Tascilar K, Hartmann F, Reiser M, Hueber AJ, Haschka J, Bayat S, Meinderink T, Knitza J, Mendez L, Hagen M, Krönke G, Rech J, Manger B, Kleyer A, Zimmermann-Rittereiser M, Schett G, Simon D, RETRO study group: Advanced machine learning for predicting individual risk of flares in rheumatoid arthritis patients tapering biologic drugs. Arthritis Res Ther. 2021;23(1):
Gottlieb AB, Mease PJ, Kirkham B, Nash P, Balsa AC, Combe B, Rech J, Zhu X, James D, Martin R, Ligozio G, Abrams K, Pricop L: Secukinumab Efficacy in Psoriatic Arthritis: Machine Learning and Meta-analysis of Four Phase 3 Trials. J Clin Rheumatol. 2021;27(6): 239-247
Valor-Méndez L, Kleyer A, Rech J, Manger B, Schett G: Long-term B-lymphocyte depletion and remission of granulomatosis with polyangiitis after two courses of rituximab treatment. Rheumatology (Oxford). 2021;60(5): e162-e164
Pinter A, Kokolakis G, Rech J, Biermann MHC, Häberle BM, Multmeier J, Reinhardt M: Hidradenitis Suppurativa and Concurrent Psoriasis: Comparison of Epidemiology, Comorbidity Profiles, and Risk Factors. Dermatol Ther (Heidelb). 2020;10(4): 721-734
Dürholz K, Hofmann J, Iljazovic A, Häger J, Lucas S, Sarter K, Strowig T, Bang H, Rech J, Schett G, Zaiss MM: Dietary Short-Term Fiber Interventions in Arthritis Patients Increase Systemic SCFA Levels and Regulate Inflammation. Nutrients. 2020;12(10):
Simon D, Tascilar K, Unbehend S, Bayat S, Berlin A, Liphardt AM, Meinderink T, Rech J, Hueber AJ, Schett G, Kleyer A: Bone Mass, Bone Microstructure and Biomechanics in Patients with Hand Osteoarthritis. J Bone Miner Res. 2020;35(9): 1695-1702
Simon D, Tascilar K, Kleyer A, Bayat S, Kampylafka E, Hueber A, Rech J, Schuster L, Engel K, Sticherling M, Schett G: STRUCTURAL ENTHESEAL LESIONS IN PSORIASIS PATIENTS ARE ASSOCIATED WITH AN INCREASED RISK OF PROGRESSION TO PSORIATIC ARTHRITIS - A PROSPECTIVE COHORT STUDY Ann Rheum Dis. 2020;79 Suppl 1(): 33-34
Friedberger A, Figueiredo C, Grimm A, d'Oliveira I, Bäuerle T, Rech J, Kleyer A, Simon D, Uder M, Schett G, Engelke K: Quantification of hand muscle volume and composition in patients with rheumatoid arthritis, psoriatic arthritis and psoriasis. BMC Musculoskelet Disord. 2020;21(1):
Renner N, Kleyer A, Krönke G, Simon D, Söllner S, Rech J, Uder M, Janka R, Schett G, Welsch GH, Pachowsky ML: T2 Mapping as a New Method for Quantitative Assessment of Cartilage Damage in Rheumatoid Arthritis. J Rheumatol. 2020;47(6): 820-825
Schett G, Bainbridge C, Berkowitz M, Davy K, Fernandes SA, Griep E, Harrison S, Gupta A, Lloyd-Hughes J, Roberts A, Layton M, Nowak NA, Patel J, Rech J, Smith JE, Watts S, Takt PP: Anti-granulocyte-macrophage colony-stimulating factor antibody otilimab in patients with hand osteoarthritis: a phase 2a randomised trial Lancet Rheumatol.. 2020;2(10): E623-E632
Raimondo MG, Rauber S, Luber M, Rigau AR, Weber S, Anchang CG, Agarwal R, Soare A, Sticherling M, Rech J, Kleyer A, Distler J, Schett G, Ramming A: TYPE 3 INNATE LYMPHOID CELLS ARE KEY DRIVERS OF PSORIATIC ARTHRITIS Ann Rheum Dis. 2020;79 Suppl 1(): 1119-1120
Rech J, Schenker H, Tascilar K, Hagen M, Mendez LV, Schoenau V, Sergeeva M, Prade J, Sulvakumar M, Konert L, Kleyer A, Simon D, Strobelt S, Behrens F, Baerwald C, Finzel S, Voll R, Hueber A, Feist E, Roesch J, da Silva JAP, Doerfler A, Damjanov N, Hess A, Schett G: Longitudinal Change in the Central Nervous System Pain Response After Treatment with Certolizumab or Placebo. a Post-hoc Analysis from the Pre-CEPRA Trial Arthritis Rheumatol. 2020;72 Suppl 10():
Steffen U, Koeleman CA, Sokolova MV, Bang H, Kleyer A, Rech J, Unterweger H, Schicht M, Garreis F, Hahn J, Andes FT, Hartmann F, Hahn M, Mahajan A, Paulsen F, Hoffmann M, Lochnit G, Munoz LE, Wuhrer M, Falck D, Herrmann M, Schett G: IgA subclasses have different effector functions associated with distinct glycosylation profiles. Nat Commun. 2020;11(1):
Stone JH, Spotswood H, Unizony S, Aringer M, Blockmans D, Brouwer E, Cid MC, Dasgupta B, Rech J, Salvarani C, Spiera R, Bao M: TIME TO FLARE AND GLUCOCORTICOID EXPOSURE IN PATIENTS WITH NEW-ONSET VERSUS RELAPSING GIANT CELL ARTERITIS TREATED WITH TOCILIZUMAB OR PLACEBO PLUS PREDNISONE TAPERING: 3-YEAR RESULTS FROM A RANDOMIZED CONTROLLED PHASE 3 TRIAL Ann Rheum Dis. 2020;79 Suppl 1(): 20-20
Bayat S, Simon D, Pecherstorfer C, Ellmann H, Figueiredo C, Englbrecht M, Hueber A, Kleyer A, Rech J, Schett G: FINE STRUCTURE ANALYSIS OF THE INTER-RELATION BETWEEN TOPHUS DEPOSITION AND BONE LESIONS IN GOUT USING A COMBINATION OF DUAL ENERGY AND HIGH-RESOLUTION CT Ann Rheum Dis. 2020;79 Suppl 1(): 1232-1232
Kampylafka E, Tascilar K, Lerchen V, Linz C, Sokolova M, Zekovic A, Kleyer A, Simon D, Rech J, Sticherling M, Schett G, Hueber AJ: Secukinumab leads to shifts from stage-based towards response-based disease clusters-comparative data from very early and established psoriatic arthritis. Arthritis Res Ther. 2020;22(1):
Schirmer JH, Aries PM, Balzer K, Berlit P, Bley TA, Buttgereit F, Czihal M, Dechant C, Dejaco C, Garske U, Henes J, Holle JU, Holl-Ulrich K, Lamprecht P, Noelle B, Moosig F, Rech J, Scheuermann K, Schmalzing M, Schmidt WA, Schneider M, Schulze-Koops H, Venhoff N, Villiger PM, Witte T, Zaenker M, Hellmich B: S2k guidelines: management of large-vessel vasculitis Z Rheumatol. 2020;79 Suppl 3(SUPPL 3): 67-95
Schirmer JH, Aries PM, Balzer K, Berlit P, Bley TA, Buttgereit F, Czihal M, Dechant C, Dejaco C, Garske U, Henes J, Holle JU, Holl-Ulrich K, Lamprecht P, Noelle B, Moosig F, Rech J, Scheuermann K, Schmalzing M, Schmidt WA, Schneider M, Schulze-Koops H, Venhoff N, Villiger PM, Witte T, Zaenker M, Hellmich B: [S2k guidelines (executive summary): management of large-vessel vasculitis]. Z Rheumatol. 2020;79(9): 937-942
Liphardt AM, Manger E, Liehr S, Bieniek L, Kleyer A, Simon D, Tascilar K, Sticherling M, Rech J, Schett G, Hueber AJ: Similar Impact of Psoriatic Arthritis and Rheumatoid Arthritis on Objective and Subjective Parameters of Hand Function. ACR Open Rheumatol. 2020;2(12): 734-740
Simon D, Tascilar K, Kleyer A, Bayat S, Kampylafka E, Hueber A, Rech J, Schuster L, Engel K, Sticherling M, Schett G: Structural Entheseal Lesions in Psoriasis Patients Are Associated with an Increased Risk Ofprogression to Psoriatic Arthritis - A Prospective Cohort Study Arthritis Rheumatol. 2020;72 Suppl 10():
Rech J, Schenker H, Tascilar K, Hagen M, Kleyer A, Simon D, Mendez LV, Schoenau V, Prade J, Sergeeva M, Sulvakumar M, Strobelt S, Konerth L, Behrens F, Baerwald C, Finzel S, Voll R, Hueber A, Roesch J, Feist E, da Silva JAP, Doerfler A, Damjanov N, Hess A, Schett G: Brain fMRI Predicts Responses to Certolizumab Pegol in RA. an International, Multi-center, Randomized, Double-blind, Placebocontrolled Trial (PreCePRA) Arthritis Rheumatol. 2020;72 Suppl 10():
Simon D, Tascilar K, Kleyer A, Bayat S, Kampylafka E, Sokolova M, Zekovic A, Hueber AJ, Rech J, Schuster L, Engel K, Sticherling M, Schett G: Structural entheseal lesions in patients with psoriasis are associated with an increased risk of progression to psoriatic arthritis. Arthritis Rheumatol. 2020;():
Sokolova MV, Simon D, Nas K, Zaiss MM, Luo Y, Zhao Y, Rech J, Schett G: A set of serum markers detecting systemic inflammation in psoriatic skin, entheseal, and joint disease in the absence of C-reactive protein and its link to clinical disease manifestations. Arthritis Res Ther. 2020;22(1):
Mclnnes LB, Mease PJ, Kivitz AJ, Nash P, Rahman P, Rech J, Conaghan PG, Kirkham B, Navarra S, Belsare AD, Delicha EM, Pricop L: Long-term efficacy and safety of secukinumab in patients with psoriatic arthritis: 5-year (end-of-study) results from the phase 3 FUTURE 2 study Lancet Rheumatol.. 2020;2(4): E227-E235
Ellmann H, Bayat S, Araujo E, Manger B, Kleyer A, Cavallaro A, Lell M, Schenker H, Simon D, Tascilar K, Baraf HSB, Schett G, Rech J: Effects of Conventional Uric Acid-Lowering Therapy on Monosodium Urate Crystal Deposits Arthritis Rheumatol. 2020;72(1): 150-156
Behrens F, Rech J, Thaçi D, Zinke S, Rothnie KJ, Oefner Daamen C, Leipe J: High rates of therapeutic changes in patients with psoriatic arthritis receiving treatment with disease-modifying antirheumatic drugs: a cross-sectional study. Mod Rheumatol. 2020;(): 1-23
Rech J, Tascilar K, Schenker H, Hagen M, Sergeeva M, Selvakumar M, Konerth L, Prade J, Strobelt S, Schonau V, Valor L, Hueber A, Simon D, Kleyer A, Behrens F, Baerwald C, Finzel S, Voll R, Feist E, Da Silva JAP, Doerfler A, Damjanov N, Hess A, Schett G: LONGITUDINAL CHANGE IN THE CENTRAL NERVOUS SYSTEM PAIN RESPONSE AFTER TREATMENT WITH CERTOLIZUMAB OR PLACEBO. A POST-HOC ANALYSIS FROM THE PRECEPRA TRIAL Ann Rheum Dis. 2020;79 Suppl 1(): 77-78
Kampylafka E, Tascilar K, Lerchen V, Linz C, Sokolova M, Zekovic A, Kleyer A, Simon D, Rech J, Sticherling M, Schett G, Hueber A: Interleukin-17 Blockade Leads to Shifts from Stage-based Towards Response-based Disease Clusters- Comparative Data from Very Early and Established Psoriatic Arthritis Arthritis Rheumatol. 2020;72 Suppl 10():
Simon D, Kleyer A, Bui CD, Hueber A, Bang H, Ramming A, Rech J, Schett G: Micro-structural bone changes are associated with broad-spectrum autoimmunity and predict the onset of rheumatoid arthritis. Arthritis Rheumatol. 2020;():
Frey S, Sticht H, Wilsmann-Theis D, Gerschütz A, Wolf K, Löhr S, Haskamp S, Frey B, Hahn M, Ekici AB, Uebe S, Thiel C, Reis A, Burkhardt H, Behrens F, Köhm M, Rech J, Schett G, Assmann G, Kingo K, Kõks S, Mössner R, Prinz JC, Oji V, Schulz P, Muñoz LE, Kremer AE, Wenzel J, Hüffmeier U: Rare Loss-of-Function Mutation in SERPINA3 in Generalized Pustular Psoriasis. J Invest Dermatol. 2020;140(7): 1451-1455.e13
Schenker H, Rech J, Tascilar K, Hagen M, Schoenau V, Sergeeva M, Selvakumar M, Konerth L, Prade J, Strobelt S, Valor L, Hueber A, Simon D, Kleyer A, Behrens F, Da Silva JAP, Baerwald C, Finzel S, Voll R, Feist E, Doerfler A, Damjanov N, Hess A, Schett G: CENTRAL NERVOUS SYSTEM PAIN RESPONSE AND COMPONENTS OF DISEASE ACTIVITY IN RA PATIENTS AFTER TREATMENT WITH CERTOLIZUMAB OR PLACEBO: A POST-HOC ANALYSIS FROM THE PRECEPRA TRIAL Ann Rheum Dis. 2020;79 Suppl 1(): 135-136
Birkner B, Rech J, Stargardt T: Cost-utility analysis of de-escalating biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis. PLoS ONE. 2020;15(1):
Liphardt AM, Manger E, Liehr S, Bieniek L, Kleyer A, Simon D, Tascilar K, Sticherling M, Rech J, Schett G, Hueber A: Similar Impact of Psoriatic Arthritis and Rheumatoid Arthritis on Objective and Subjective Parameters of Hand Function Arthritis Rheumatol. 2020;72 Suppl 10():
Rech J, Tascilar K, Schenker H, Sergeeva M, Selvakumar M, Konerth L, Prade J, Strobelt S, Hagen M, Schonau V, Valor L, Hueber A, Simon D, Kleyer A, Behrens F, Da Silva JAP, Baerwald C, Finzel S, Voll R, Feist E, Doerfler A, Damjanov N, Hess A, Schett G: PREDICTION OF RESPONSE TO CERTOLIZUMAB PEGOL TREATMENT BY FUNCTIONAL MRI OF THE BRAIN: AN INTERNATIONAL, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (PRECEPRA) Ann Rheum Dis. 2020;79 Suppl 1(): 952-952
Hueffmeier UD, Loehr S, Uebe S, Popp B, Bowes J, Kirchner P, Giardina E, Korendowych E, Ekici AB, Ho P, Behrens F, Koehm M, Schett G, Rech J, Assmann G, Nimeh A, Padyukov L, Alenius G, McHugh NJ, Sticht H, Burkhardt H, Barton A, Reis A: Common RUNX3 missense variant contributes to psoriatic arthritis by affecting splicing and modifying signaling, activation and differentiation of T-cells Eur J Hum Genet. 2020;28 Suppl 1(SUPPL 1): 314-315
Rossmanith T, Koehm M, Kiltz U, Rech J, Burmester GR, Kellner H, Bulczak-Schadendorf A, Foldenauer AC, Burkhardt H, Behrens F: IMPACT OF METHOTREXATE ON DISEASE PATTERN IN ACTIVE PSORIATIC ARTHRITIS PATIENTS ELIGIBLE FOR A RANDOMIZED CLINICAL TRIAL WITH USTEKINUMAB: COMPARATIVE BASELINE DATA FROM MULTICENTRE INVESTIGATOR-INITIATED MUST TRIAL Ann Rheum Dis. 2020;79 Suppl 1(): 773-773
Simon D, Haschka J, Muschitz C, Kocijan A, Baierl A, Kleyer A, Schett G, Kapiotis S, Resch H, Sticherling M, Rech J, Kocijan R: Bone microstructure and volumetric bone mineral density in patients with hyperuricemia with and without psoriasis. Osteoporos Int. 2020;31(5): 931-939
Pecherstorfer C, Simon D, Unbehend S, Ellmann H, Englbrecht M, Hartmann F, Figueiredo C, Hueber A, Haschka J, Kocijan R, Kleyer A, Schett G, Rech J, Bayat S: A Detailed Analysis of the Association between Urate Deposition and Erosions and Osteophytes in Gout. ACR Open Rheumatol. 2020;2(10): 565-572
Stone JH, Han J, Unizony S, Aringer M, Blockmans D, Brouwer E, Cid MC, Dasgupta B, Rech J, Salvarani C, Spiera R, Bao M: MAINTAINED BENEFIT IN HEALTH-RELATED QUALITY OF LIFE OF PATIENTS WITH GIANT CELL ARTERITIS TREATED WITH TOCILIZUMAB PLUS PREDNISONE TAPERING: RESULTS FROM THE OPEN-LABEL, LONG-TERM EXTENSION OF A PHASE 3 RANDOMIZED CONTROLLED TRIAL Ann Rheum Dis. 2020;79 Suppl 1(): 1077-1078
Mease PJ, Kavanaugh A, Reimold A, Tahir H, Rech J, Hall S, Geusens P, Pellet P, Delicha EM, Pricop L, Mpofu S, FUTURE 1 study group: Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Psoriatic Arthritis: Final 5-year Results from the Phase 3 FUTURE 1 Study. ACR Open Rheumatol. 2020;2(1): 18-25
Rech J, Sticherling M, Stoessel D, Biermann MHC, Häberle BM, Reinhardt M: Psoriatic arthritis epidemiology, comorbid disease profiles and risk factors: results from a claims database analysis. Rheumatol Adv Pract. 2020;4(2):
Stone JH, Neumann T, Spotswood H, Unizony SH, Aringer M, Blockmans D, Brouwer E, Cid MC, Dasgupta B, Rech J, Salvarani C, Spiera R, Bao M: Time to Flare in Patients With New-Onset Versus Relapsing Giant Cell Arteritis Treated With Tocilizumab or Placebo Plus Prednisone Tapering: 3-Year Results From a Randomized Controlled Phase 3 Trial Swiss Med Wkly. 2020;(): 5S-5S
Hagen M, Englbrecht M, Haschka J, Reiser M, Kleyer A, Hueber A, Manger B, Figueiredo C, Cobra JF, Tony HP, Finzel S, Kleinert S, Wendler J, Schuch F, Ronneberger M, Feuchtenberger M, Fleck M, Manger K, Ochs W, Lorenz HM, Nüsslein H, Alten R, Henes J, Krüger K, Schett G, Rech J: Cost-effective Tapering Algorithm in Patients with Rheumatoid Arthritis: Combination of Multibiomarker Disease Activity Score and Autoantibody Status. J Rheumatol. 2019;46(5): 460-466
Kampylafka E, Englbrecht M, Tascilar K, Lerchen V, Linz C, Kleyer A, Simon D, Rech J, Schett G, Hueber A: COMPARATIVE CHANGE IN QUALITY OF LIFE MEASURES IN PRECLINICAL AND ESTABLISHED PSORIATIC ARTHRITIS PATIENTSUNDER SECUKINUMAB TREATMENT. DATA DERIVED FROM THE PROSPECTIVE OPEN LABEL PSARTROS STUDY Ann Rheum Dis. 2019;78(): 1845-1845
Mease PJ, Kavanaugh A, Reimold A, Tahir H, Rech J, Hall S, Geusens P, Pellet P, Delicha EM, Pricop L, Mpofu S: SECUKINUMAB PROVIDES SUSTAINED IMPROVEMENTS IN THE SIGNS AND SYMPTOMS IN PSORIATIC ARTHRITIS: FINAL 5 YEAR EFFICACY AND SAFETY RESULTS FROM A PHASE 3 TRIAL Ann Rheum Dis. 2019;78 Suppl 2(): 917-917
Valor L, Schenker H, Hagen M, Knitza J, Rech J, Schett G: THE ANTI-RO52 PREVALENCE IN THE SJOGREN'S SYNDROME PICTURE: A SINGLE CENTER CROSS SECTIONAL STUDY Ann Rheum Dis. 2019;78(): 1180-1180
Löhr S, Ekici AB, Uebe S, Büttner C, Köhm M, Behrens F, Böhm B, Sticherling M, Schett G, Simon D, Mössner R, Nimeh A, Oji V, Assmann G, Rech J, Holmdahl R, Burkhardt H, Reis A, Hüffmeier U: Analyses of association of psoriatic arthritis and psoriasis vulgaris with functional NCF1 variants. Rheumatology (Oxford). 2019;58(5): 915-917
Kampylafka E, Oliveira I, Linz C, Lerchen V, Englbrecht M, Simon D, Rech J, Kleyer A, Schett G, Sticherling M, Hueber AJ: Interleukin 17 Blockade in Psoriasis Patients with Subclinical Joint Inflammation- Prospective Open Study to Influence the Course of the Disease by means of Secukinumab J Dtsch Dermatol Ges. 2019;17(): 127-128
Stephan M, Tascilar K, Hagen M, Haschka J, Reiser M, Hartmann F, Kleyer A, Hueber A, Manger B, Figuereido C, Cobra J, Tony HP, Finzel S, Kleinert S, Wendler J, Schuch F, Ronneberger M, Feuchtenberger M, Fleck M, Manger K, Ochs W, Schmitt-Haendle M, Lorenz HM, Nuesslein H, Alten R, Henes J, Krueger K, Schett G, Rech J: PHYSICAL FUNCTION IN RA PATIENTS IN REMISSION UNDERGOING TAPERING AND/OR STOPPING OF DMARDS Ann Rheum Dis. 2019;78(): 321-322
Neumann T, Stone JH, Bao M, Han J, Aringer M, Blockmans D, Brouwer E, Cid MC, Dasgupta B, Rech J, Salvarani C, Spiera R, Unizony SH: Long-term outcome of tocilizumab for patients with giant cell arteritis: Results from part 2 of the GiACTA trial Swiss Med Wkly. 2019;(): 15S-15S
Valor L, Schenker H, Hagen M, Knitza J, Rech J, Schett G: POLYAUTOIMMUNITY AND MAJOR ORGAN INVOLVEMENT PREVALENCE IN SJOGREN'S SYNDROME: THYROID, LIVER, LUNG AND KIDNEY AS TARGETS. A SINGLE CENTER CROSS SECTIONAL STUDY Ann Rheum Dis. 2019;78(): 1744-1745
de Moel E, Rech J, Mahler M, Roth J, Schouffoer A, Ronday K, Huizinga T, Allaart CF, Toes R, Schett G, van der Woude D: Serum Calprotectin Is a Prognostic Marker for Drug-Free Remission in RA Arthritis Rheumatol. 2019;71():
Hannemann N, Cao S, Eriksson D, Schnelzer A, Jordan J, Eberhardt M, Schleicher U, Rech J, Ramming A, Uebe S, Ekici A, Canete JD, Chen XX, Baeuerle T, Vera J, Bogdan C, Schett G, Bozec A: Transcription factor Fra-1 targets arginase-1 to enhance macrophage-mediated inflammation in arthritis. J Clin Invest. 2019;129(7): 2669-2684
Tahir H, Mease PJ, Kavanaugh A, Reimold A, Rech J, Hall S, Geusens P, Pellet P, Delicha EM, Pricop L, Mpofu S: SECUKINUMAB PROVIDES SUSTAINED IMPROVEMENTS IN THE SIGNS AND SYMPTOMS IN PSORIATIC ARTHRITIS: FINAL 5-YEAR EFFICACY AND SAFETY RESULTS FROM THE FUTURE 1 PHASE 3 TRIAL Rheumatology (Oxford). 2019;58 Suppl 3(): 151-151
Hueffmeier UD, Loehr S, Ekici AB, Uebe S, Koehm M, Behrens F, Boehm B, Sticherling M, Schett G, Moessner R, Nimeh A, Assmann G, Rech J, Oji V, Holmdahl R, Burkhardt H, Reis A: Association analyses of functional NCF1 variants in psoriatic arthritis and psoriasis vulgaris Eur J Hum Genet. 2019;27(): 125-125
Sokolova M, Nas K, Luo YB, Simon D, Zhao Y, Rech J, Zaiss M, Schett G: A SET OF INFLAMMATORY MARKERS ALLOWING TO DETECT SYSTEMIC INFLAMMATION IN PSORIATIC SKIN, ENTHESEAL AND JOINT DISEASE IN THE ABSENCE OF CRP AND THEIR LINK TO CLINICAL DISEASE MANIFESTATION Ann Rheum Dis. 2019;78(): 175-176
Schonau V, Roth J, Tascilar K, Rech J, Schmidt D, Kuwert T, Crescentini F, Boiardi L, Casali MI, Versari A, Schett G, Salvarani C, Muratore F: RESOLUTION OF VASCULAR INFLAMMATION IN PATIENTS WITH GIANT CELL ARTERITIS RECEIVING GLUCOCORTICOIDS, METHOTREXATE OR TOCILIZUMAB TREATMENT-DATA FROM THE ITALIAN/GERMAN RIGA STUDY Ann Rheum Dis. 2019;78(): 591-591
Schoenau V, Roth J, Tascilar K, Rech J, Schmidt D, Kuwert T, Crescentini F, Boiardi L, Casali M, Verson A, Pazzola G, Schett G, Salvarani C, Muratore F: Resolution of Vascular Inflammation in Patients with Giant Cell Arteritis Receiving Glucocorticoids, Methotrexate or Tocilizumab Treatment: Data from the Italian/German RIGA Study Arthritis Rheumatol. 2019;71():
Gottlieb A, Mease P, Kirkham B, Nash P, Balsa A, Combe B, Rech J, Ruvie M, Ligozio G, Abrams K, Pricop L: Seculdnumab efficacy in psoriatic arthritis: individual patient meta analysis of four phase 3 trials in 2049 patients J Eur Acad Dermatol Venereol. 2019;33 Suppl 3(): 83-84
Kampylafka E, Simon D, d'Oliveira I, Linz C, Lerchen V, Englbrecht M, Rech J, Kleyer A, Sticherling M, Schett G, Hueber AJ: Disease interception with interleukin-17 inhibition in high-risk psoriasis patients with subclinical joint inflammation-data from the prospective IVEPSA study. Arthritis Res Ther. 2019;21(1):
Bayat S, Ellmann H, Araujo E, Manger B, Hagen M, Kleyer A, Cavallaro A, Lell M, Schenker H, Simon D, Tascilar K, Baraf HSB, Schett G, Rech J: SIZE MATTERS - EXTENT OF MONOSODIUM URATE DEPOSITS BUT NOT SERUM URATE LEVEL PREDICTS COMPLETE RESOLUTION OF MONOSODIUM URATE CRYSTAL DEPOSITS IN PATIENTS WITH GOUT Ann Rheum Dis. 2019;78(): 1295-1296
Valor L, Schenker H, Knitza J, Hagen M, Rech J, Schett G: The anti-Ro52 Prevalence in the Sjogren's Syndrome Picture: A Single Center Cross Sectional Study Arthritis Rheumatol. 2019;71():
Simon D, Kleyer A, Bayat S, Tascilar K, Kampylafka E, Meinderink T, Schuster L, Petrov R, Liphardt AM, Rech J, Schett G, Hueber AJ: Effect of disease-modifying anti-rheumatic drugs on bone structure and strength in psoriatic arthritis patients Arthritis Res Ther. 2019;21():
Stone JH, Tuckwell K, Dimonaco S, Klearman M, Aringer M, Blockmans D, Brouwer E, Cid MC, Dasgupta B, Rech J, Salvarani C, Schulze-Koops H, Schett G, Spiera R, Unizony SH, Collinson N: ACUTE PHASE REACTANT LEVELS AND PREDNISONE DOSES AT DISEASE FLARE IN PATIENTS WITH GIANT CELL ARTERITIS: PROSPECTIVE DATA FROM THE GIACTA TRIAL Rheumatology (Oxford). 2019;58():
Berlin A, Simon D, Tascilar K, Figueiredo C, Bayat S, Finzel S, Klaus E, Rech J, Hueber AJ, Kleyer A, Schett G: The ageing joint-standard age- and sex-related values of bone erosions and osteophytes in the hand joints of healthy individuals. Osteoarthritis Cartilage. 2019;27(7): 1043-1047
Kleyer A, Simon D, Bui CD, Hueber A, Bang H, Ramming A, Rech J, Kroenke G, Schett G: MICRO-STRUCTURAL CHANGES ASSOCIATED WITH ANTI-CITRULLINATED VIMENTIN AUTOIMMUNITY IN RA-AT-RISK INDIVIDUALS PRECIPITATE THE ONSET OF RHEUMATOID ARTHRITIS Ann Rheum Dis. 2019;78(): 133-133
Moosig F, Schmalzing M, Aries PM, Henes J, Lamprecht P, Rech J, Witte T: [Actual Treatment Options for Giant Cell Arteritis]. Dtsch Med Wochenschr. 2019;144(9): 595-600
Simon D, Berlin A, Tascilar K, Bayat S, Engelke K, Rech J, Figuereido C, Hueber A, Schett G, Kleyer A: THE PHYSIOLOGICAL FINGER JOINT ARCHITECTURE - AGE-RELATED INCREASE OF EROSIONS AND OSTEOPHYTES IN THE JOINTS OF HEALTHY INDIVIDUALS Ann Rheum Dis. 2019;78(): 602-603
Rech J, Sticherling M, Biermann M, Haeberle B, Reinhardt M: Psoriatic Arthritis - Epidemiology, Incidence Rate in Psoriasis Patients, Comorbidity Profiles and Risk Factor Analysis Arthritis Rheumatol. 2019;71 Suppl 10():
Riechers E, Baerlecken N, Baraliakos X, Achilles-Mehr Bakhsh K, Aries P, Bannert B, Becker K, Brandt-Jürgens J, Braun J, Ehrenstein B, Euler HH, Fleck M, Hein R, Karberg K, Köhler L, Matthias T, Max R, Melzer A, Meyer-Olson D, Rech J, Rockwitz K, Rudwaleit M, Schmidt RE, Schweikhard E, Sieper J, Stille C, von Hinüber U, Wagener P, Weidemann HF, Zinke S, Witte T: Sensitivity and Specificity of Autoantibodies Against CD74 in Nonradiographic Axial Spondyloarthritis. Arthritis Rheumatol. 2019;71(5): 729-735
Liphardt AM, Liehr S, Manger E, Bieniek L, Kleyer A, Simon D, Tascilar K, Sticherling M, Rech J, Schett G, Hueber A: HAND FUNCTION IS IMPAIRED IN PATIENTS WITH RHEUMATOID ARTHRITIS, PSORIATIC ARTHRITIS, AND PSORIASIS COMPARED TO HEALTHY CONTROLS Ann Rheum Dis. 2019;78(): 2126-2126
Simon D, Tascilar K, Unbehend S, Bayat S, Meinderink T, Berlin A, Rech J, Hueber A, Schett G, Kleyer A: IMPACT OF PRIMARY HAND OSTEOARTHRITIS ON MICROSTRUCTURE AND BIOMECHANICS IN FINGER JOINTS Ann Rheum Dis. 2019;78(): 1868-1868
Stone J, Spotswood H, Unizony S, Aringer M, Blockmans D, Brouwer E, Cid MC, Dasgupta B, Rech J, Salvarani C, Spiera R, Bao M: Time to Flare in Patients with New-Onset versus Relapsing Giant Cell Arteritis Treated with Tocilizumab or Placebo Plus Prednisone Tapering: 3-Year Results from a Randomized Controlled Phase 3 Trial Arthritis Rheumatol. 2019;71 Suppl 10():
Stone JH, Tuckwell K, Dimonaco S, Klearman M, Aringer M, Blockmans D, Brouwer E, Cid MC, Dasgupta B, Rech J, Salvarani C, Schulze-Koops H, Schett G, Spiera RF, Unizony SH, Collinson N: EFFECTS OF BASELINE PREDNISONE DOSE ON REMISSION AND DISEASE FLARE IN PATIENTS WITH GIANT CELL ARTERITIS TREATED WITH TOCILIZUMAB IN THE GIACTA TRIAL Rheumatology (Oxford). 2019;58():
Finzel S, Kraus S, Figueiredo CP, Regensburger A, Kocijan R, Rech J, Schett G: Comparison of the effects of tocilizumab monotherapy and adalimumab in combination with methotrexate on bone erosion repair in rheumatoid arthritis. Ann Rheum Dis. 2019;78(9): 1186-1191
Stone J, Han J, Unizony S, Aringer M, Blockmans D, Brouwer E, Cid MC, Dasgupta B, Rech J, Salvarani C, Spiera R, Bao M: Maintained Benefit in Health-Related Quality of Life of Patients with Giant Cell Arteritis Treated with Tocilizumab Plus Prednisone Tapering: Results from the Open-Label, Long-Term Extension of a Phase 3 Randomized Controlled Trial Arthritis Rheumatol. 2019;71 Suppl 10():
Haschka J, Simon D, Bayat S, Kleyer A, Kampylafka E, Hueber A, Muschitz C, Skalicky S, Hackl M, Resch H, Schett G, Kocijan R, Rech J: Identification of Circulating MicroRNA Signatures in Patients with Psoriasis and Psoriatic Arthritis to Develop Novel Strategies for Early Diagnosis of a Bone and Joint Involvement Arthritis Rheumatol. 2019;71():
Hannemann N, Cao S, Schnelzer A, Jordan J, Eberhardt M, Schleicher U, Uebe S, Ekici A, Rech J, Baeuerle T, Bogdan C, Vera J, Schett G, Bozec A: INHIBITION OF ARGINASE-1 EXPRESSION BY THE TRANSCRIPTION FACTOR FRA-1 IN MACROPHAGES EXACERBATES RHEUMATOID ARTHRITIS INFLAMMATION Ann Rheum Dis. 2019;78(): A27-A27
Stone J, Bao M, Han J, Aringer M, Blockmans D, Brouwer E, Cid MC, Dasgupta B, Rech J, Salvarani C, Spiera R, Unizony S: Long-Term Outcome of Tocilizumab for Patients with Giant Cell Arteritis: Results from Part 2 of a Randomized Controlled Phase 3 Trial Arthritis Rheumatol. 2019;71 Suppl 10():
Haeger J, Bang H, Hagen M, Frech M, Traeger P, Sokolova MV, Steffen U, Tascilar K, Sarter K, Schett G, Rech J, Zaiss MM: The Role of Dietary Fiber in Rheumatoid Arthritis Patients: A Feasibility Study Nutrients. 2019;11(10):
Schett G, Simon D, Hueber A, Bang H, Rech J, Kroenke G, Kleyer A: Anti-citrullinated Vimentin Antibodies Are Associated to Early Deterioration of Cortical Bone and Volumetric Bone Mineral Density in Finger Joints in RA-at-risk Patients Arthritis Rheumatol. 2019;71():
Stone J, Tuckwell K, Dimonaco S, Klearman M, Aringer M, Blockmans D, Brouwer E, Cid M, Dasgupta B, Rech J, Salvarani C, Schulze-Koops H, Schett G, Spiera R, Unizony S, Collinson N: EFFECTS OF BASELINE PREDNISONE DOSE ON REMISSION AND DISEASE FLARE IN PATIENTS WITH GIANT CELL ARTERITIS TREATED WITH TOCILIZUMAB IN A PHASE 3 RANDOMIZED CONTROLLED TRIAL Rheumatology (Oxford). 2019;58():
Hagen M, Tascilar K, Reiser M, Haschka J, Kleyer A, Valor L, Manger B, Schett G, Rech J: Prediction of Disease Relapses by Multi-biomarker Disease Activity Score and Autoantibody Status in RA Patients Tapering DMARD Treatment in Stable Remission Arthritis Rheumatol. 2019;71():
Simon D, Bayat S, Tascilar K, Kampylafka E, Meinderink T, Schuster L, Liphardt AM, Rech J, Hueber A, Schett G, Kleyer A: EFFECT OF DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS ON BONE STRUCTURE AND STRENGTH IN PSORIATIC ARTHRITIS PATIENTS Ann Rheum Dis. 2019;78(): 1287-1287
Araujo EG, Englbrecht M, Hoepken S, Finzel S, Kampylafka E, Kleyer A, Bayat S, Schoenau V, Hueber A, Rech J, Schett G: Effects of ustekinumab versus tumor necrosis factor inhibition on enthesitis: Results from the enthesial clearance in psoriatic arthritis (ECLIPSA) study. Semin Arthritis Rheum. 2019;48(4): 632-637
Stone JH, Tuckwell K, Dimonaco S, Klearman M, Aringer M, Blockmans D, Brouwer E, Cid MC, Dasgupta B, Rech J, Salvarani C, Schulze-Koops H, Schett G, Spiera R, Unizony SH, Collinson N: Glucocorticoid Dosages and Acute-Phase Reactant Levels at Giant Cell Arteritis Flare in a Randomized Trial of Tocilizumab. Arthritis Rheumatol. 2019;71(8): 1329-1338
Boeltz S, Hagen M, Knopf J, Mahajan A, Schick M, Zhao Y, Erfurt-Berge C, Rech J, Munoz LE, Herrmann M: Towards a pro-resolving concept in systemic lupus erythematosus Semin Immunopathol. 2019;41(6): 681-697
Valor L, Hagen M, Reiser M, Hartmann F, Kleyer A, Manger B, Schett G, Rech J, Tascilar K: Factors Associated with Persistent Drug-free Remission in Patients with Rheumatoid Arthritis Arthritis Rheumatol. 2019;71():
Valor L, Schenker H, Knitza J, Hagen M, Rech J, Schett G: Polyautoimmunity and Major Organ Involvement Prevalence in Sjogren's Syndrome: Thyroid, Liver, Lung and Kidney as Targets. a Single Center Cross Sectional Study Arthritis Rheumatol. 2019;71():
de Moel EC, Rech J, Mahler M, Roth J, Vogl T, Schouffoer A, Goekoop RJ, Huizinga TWJ, Allaart CF, Toes REM, Schett G, van der Woude D: Circulating calprotectin (S100A8/A9) is higher in rheumatoid arthritis patients that relapse within 12 months of tapering anti-rheumatic drugs Arthritis Res Ther. 2019;21(1):
McInnes IB, Kivitz AJ, Nash P, Rahman P, Rech J, Kirkham B, Navarra S, Ding K, Ilsley E, Pricop L: SECUKINUMAB PROVIDES SUSTAINED IMPROVEMENTS IN THE SIGNS AND SYMPTOMS OF ACTIVE PSORIATIC ARTHRITIS: LONG-TERM (4-YEAR) DATA FROM A PHASE 3 STUDY J Clin Rheumatol. 2019;25 Suppl 3(): S5-S5
Valor L, Hagen M, Reiser M, Kleyer A, Hartmann F, Manger B, Schett G, Rech J, Tascilar K, Haschka J, Englbrecht M, Hueber A, Figueiredo C, Fogagnolo J, Tony HP, Finzel S, Kleinert S, Wendler J, Schuch F, Ronneberger M, Feuchtenberger M, Fleck M, Manger K, Ochs W, Schmitt-Haendle M, Lorenz HM, Nuesslein H, Alten R, Henes J, Krueger K, Retro: FACTORS ASSOCIATED WITH PERSISTENT DRUG-FREE REMISSION IN PATIENTS WITH RHEUMATOID ARTHRITIS Ann Rheum Dis. 2019;78(): 730-730
Schoenau V, Roth J, Englbrecht M, Rech J, Schett G: Does an 18f-FDG-PET/CT in Patients with Giant Cell Arteritis in Clinical Remission Make Sense? Arthritis Rheumatol. 2018;70():
Mease PJ, Kavanaugh A, Reimold A, Tahir H, Rech J, Hall S, Geusens P, Pascale P, Delicha EM, Pricop L, Mpofu S: Secukinumab Provides Sustained Improvements in the Signs and Symptoms in Psoriatic Arthritis: Final 5 Year Efficacy and Safety Results from a Phase 3 Trial Arthritis Rheumatol. 2018;70():
Stone JH, Tuckwell K, Dimonaco S, Klearman M, Aringer M, Blockmans D, Brouwer E, Cid MC, Dasgupta B, Rech J, Salvarani C, Schulze-Koops H, Schett G, Spiera RF, Unizony SH, Collinson N: Effects of Baseline Prednisone Dose on Remission and Disease Flare in Patients with Giant Cell Arteritis Treated with Tocilizumab in a Phase 3 Randomized Controlled Trial Arthritis Rheumatol. 2018;70():
Mease P, Kirkham B, Nash P, Balsa A, Combe B, Rech J, Martin R, Ligozio G, Abrams K, Pricop L: SECUKINUMAB EFFICACY IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: META-ANALYSIS OF 4 PHASE 3 TRIALS Acta Derm Venereol. 2018;98(): 15-16
Gabay C, Fautrel B, Rech J, Spertini F, Feist E, Kötter I, Hachulla E, Morel J, Schaeverbeke T, Hamidou MA, Martin T, Hellmich B, Lamprecht P, Schulze-Koops H, Courvoisier DS, Sleight A, Schiffrin EJ: Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still's disease. Ann Rheum Dis. 2018;77(6): 840-847
Schett G, Finze S, Kraus S, Regensburger A, Kocijan R, Rech J: TOCILIZUMAB ACHIEVES BETTER REPAIR OF FOCAL BONE EROSIONS THAN TUMOUR NECROSIS FACTOR INHIBITION IN RA PATIENTS - DATA FROM THE PROSPECTIVE REBONE STUDY ON EROSION REPAIR Ann Rheum Dis. 2018;77(): 572-572
Kampylafka E, Oliveira I, Linz C, Lerchen V, Englbrecht M, Simon D, Sticherling M, Rech J, Kleyer A, Schett G, Hueber AJ: Disease Interception in Psoriasis Patients with Subclinical Joint Inflammation By Interleukin 17 Inhibition with Secukinumab - Data from a Prospective Open Label Study Arthritis Rheumatol. 2018;70():